Clinicopathological Study of PD-1/PD-L1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with Emphasis on Large B-Cell Richter Transformation

Volume 24, Issue 12, December 2023, Pages 4243-4252

Rokia Masoud; Ahmed E Eladl; Shaimaa El-Ashwah; Ahmed Abbas; Wageeha Kandil

• View Article
• PDF 3.2 M

Evaluation of HHLA2 and CD8 Immunohistochemical Expression in Colorectal Carcinoma and Their Prognostic Significance

Volume 24, Issue 12, December 2023, Pages 4309-4319

Zeinab Mohammed Gawesh; Eman Mohamad Ibrahim; Hend Mohamed Hamdey Rashed ElKalla; Azmy Abdel Hamid Awad; Mie Ali Mohamed

• View Article
• PDF 1.77 M

Effect of Primary Systemic Therapy on PD-1, PD-L1, and PD-L2 mRNA Expression in Advanced Breast Cancer

Volume 22, Issue 7, July 2021, Pages 2069-2077

Ramadhan Karsono; Muhammad Al Azhar; Yulia Pratiwi; Fahreza Saputra; Siti Nadliroh; Teguh Aryandono

• View Article
• PDF 535.27 K

Human Endogenous Retrovirus-H Long Terminal Repeat- Associating Protein 2 (HHLA2) is a Novel Immune Checkpoint Protein in Lung Cancer which Predicts Survival

Volume 22, Issue 6, June 2021, Pages 1883-1889

Mayada Saad Farrag; Eman Mohamad Ibrahim; Tamer A. El-Hadidy; Mohamed Farouk Akl; Alyaa R. Elsergany; Heba Wagih Abdelwahab

• View Article
• PDF 548.96 K

The Clinical Value of VDR and CTLA 4 in Evaluating the Prognosis of Invasive Duct Carcinoma of Egyptian Patients and their Benefit as a Target Therapy

Volume 22, Issue 4, April 2021, Pages 1183-1194

Nanis Shawky Holah

• View Article
• PDF 1.38 M

Role of Immunotherapy in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung

Volume 22, Issue 2, February 2021, Pages 365-370

Takefumi Komiya; Neema Ravindra; Emily Powell

• View Article
• PDF 360.72 K

Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma

Volume 20, Issue 10, October 2019, Pages 2951-2957

Deepika Chandrasekaran; Sandhya Sundaram; Kadhiresan N; Padmavathi R

• View Article
• PDF 710.73 K

Programmed Death Ligand 1 (PD-L1) Expression in Epithelial Ovarian Cancer: A Comparison of Type I and Type II Tumors

Volume 20, Issue 4, April 2019, Pages 1161-1169

Wilasinee Nhokaew; Pilaiwan Kleebkaow; Nipon Chaisuriya; Chumnan Kietpeerakool

• View Article
• PDF 706.96 K

Increased Tumour Infiltration of CD4+ and CD8+ T-Lymphocytes in Patients with Triple Negative Breast Cancer Suggests Susceptibility to Immune Therapy

Volume 18, Issue 7, July 2017, Pages 1827-1832

Bushra Sikandar; Muhammad Asif Qureshi; Saima Naseem; Saeed Khan; Talat Mirza

• View Article
• PDF 806.7 K

Expression of Cancer-Testis Antigens in Pediatric Cancers

Volume 16, Issue 13, December 2015, Pages 5149-5152

• View Article
• PDF 346.15 K

FHIT Gene Expression in Acute Lymphoblastic Leukemia and its Clinical Significance

Volume 16, Issue 18, December 2015, Pages 8197-8201

• View Article
• PDF 426.19 K

Expression of Cancer-Testis Antigens in Stem Cells: Is it a Potential Drawback or an Advantage in Cancer Immunotherapy

Volume 16, Issue 7, July 2015, Pages 3079-3081

• View Article
• PDF 281.39 K

Dendritic Cells Induce Specific Cytotoxic T Lymphocytes against Prostate Cancer TRAMP-C2 Cells Loaded with Freezethaw Antigen and PEP-3 Peptide

Volume 16, Issue 2, February 2015, Pages 571-578

• View Article
• PDF 1.94 M

Development and Clinical Evaluation of Dendritic Cell Vaccines or HPV Related Cervical Cancer - a Feasibility Study

Volume 15, Issue 14, December 2014, Pages 5909-5916

• View Article
• PDF 870 K

Anti-tumor Efficacy of a Hepatocellular Carcinoma Vaccine Based on Dendritic Cells Combined with Tumor-derived Autophagosomes in Murine Models

Volume 14, Issue 5, May 2013, Pages 3109-3116

• View Article
• PDF 1.86 M

Immunotherapeutic Approach for Better Management of Cancer - Role of IL-18

Volume 13, Issue 11, November 2012, Pages 5353-5361

• View Article
• PDF 587.54 K

Snake Venom: A Potent Anticancer Agent

Volume 13, Issue 10, October 2012, Pages 4855-4860

• View Article
• PDF 381.43 K

Enhanced Induction of Anti-tumor CTLs in Vitro by a Lentivirus-tranduced Dendrtic Cell Vaccine Expressing Secondary Lymphoid Tissue Chemokine and Mucin 1

Volume 12, Issue 11, November 2011, Pages 2811-2817

• View Article
• PDF 937.26 K

Preclinical Changes in Immunoreactivity and Cellular Architecture during the Progressive Development of Intracranial Neoplasms and an Immunotherapeutic Schedule with a Novel Biological Response Modifier, the T11TS / S-

Volume 3, Issue 4, April 2002, Pages 325-337

• View Article
• PDF 384.57 K